EUCTR2006-000068-10-BE进行中（未招募）不适用
A DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE SAFETY AND EFFICACY OF 75 MG AND 150 MG DOSES OF ERB-041 ON THE REDUCTION OF SYMPTOMS ASSOCIATED WITH ENDOMETRIOSIS DURING TREATMENT AND POST TREATMENT IN REPRODUCTIVE-AGED WOME
Wyeth Research Division of Wyeth Pharmaceuticals Inc.0 个研究点目标入组 150 人开始时间: 2006年5月10日最近更新:
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •Subjects must have had a surgical diagnosis (laparoscopy or laparotomy) of endometriosis established within 10 years before visit 1B (screening). Operative report review will be required for verification. If multiple surgeries have been performed within the previous 10 years, the operative report of the most recent laparoscopy or laparotomy will be used for eligibility requirements and source documentation.
- •·-Subjects must be nonpregnant, nonlactating women aged 18 to 45 years, inclusive, at the time of visit 1B (screening).
- •·- Subjects not undergoing a washout from oral contraceptives must have a history of regular menstrual periods (3 or more consecutive days of uterine bleeding requiring sanitary protection), with cycle lengths of 21 to 35 days, for at least 3 consecutive months before visit 1B (screening).
- •·- After discontinuation of oral contraceptives, subjects must have had 1 spontaneous period (ie, after the oral contraceptives withdrawal bleed) before visit 1B (screening).
- •·- Subjects must be sexually active (vaginal intercourse). Sexually active” is defined as full vaginal penetration at least 2 times per month or 2 failed attempts at vaginal intercourse.
- •·- Subjects must be willing to use highly effective nonhormonal methods of birth control (eg, sterilization, diaphragm with spermicide, or condom with spermicide) for the duration of study participation.
- •·- Subject must have a telephone line (analog preferred) or wireless communication instrument.
- •·- Subject should be able to understand the use of a personal digital assistant (PDA) device.
- •·- In the opinion of the investigator, the subject will comply with the protocol and has a high probability of completing the study.
- •·- Subjects must be willing to refrain from the use of prohibited medications during the treatment and posttreatment phases of the study.
- •·- During the treatment phase, subjects must be willing to use no more than the rescue medication regimen historically established during the pretreatment phase.
- •·- Rescue medication is limited to intake of 1 dose of analgesic per episode. If pain recurs, the subject is permitted to take a dose for each recurring episode up to the daily recommended dose for that rescue medication. Chronic narcotic use is not permitted.
- •·- Subjects must exhibit a positive response regarding the symptom of pelvic pain. A positive response is reported by the subject, reflects the worst episode before analgesic use, and is determined as follows:
- •oAt Visit 1B (Screening):
- •i.Subjects must have moderate to severe pelvic pain for at least 3 months before visit 1B (screening), as exhibited by a pelvic pain score of 3 or 4 on the B&B scale (the B&B scale includes the symptom of pelvic pain and assigns a point score for the degree of reported severity); AND
- •ii.The subject must report a pelvic pain score of at least 4 on the numeric rating scale (NRS, question 3) included in the Pelvic Pain Classification Tool (PPCT) on the basis of 1-month recall of the severity of her nonmenstrual pelvic pain before taking pain medication (if applicable).
- •oAt Visit 2 (Randomization):
- •i.The subject must have a pelvic pain score of 3 or 4 on the B&B scale (this pelvic pain score will be considered baseline); AND
- •ii.The subject must report a pelvic pain score of at least 4 on the NRS on the basis of 1-month recall of the severity of her nonmenstrual pelvic pain before taking pain medication (if applicable).
- •·- Subjects must sign and date an institution
排除标准
- •Subjects who desire to become pregnant during the study.
- •- Subjects who have undergone hysterectomy and/or bilateral oophorectomy
- •- Subjects who are not candidates for estrogen therapy.
- •- Subjects who are pregnant or who were pregnant before visit 1B (screening).
- •- Subjects who are breastfeeding.
- •- Subjects who are not sexually active.
- •- The use of the following drugs within 30 days before visit 1B (screening):
- •a.Oral contraceptives, dermal patch containing contraceptives, injectable or implantable or insertable contraceptive hormones.
- •b.Oral, transdermal, or vaginally applied estrogens, progestogens, and/or androgens.
- •c.Aromatase inhibitors (eg, anastrozole).
- •- The use of the following drugs within 90 days before visit 1B (screening):
- •a.Progestin containing intrauterine device (IUD).
- •b.Monthly dose gonadotropin-releasing hormone (GnRH) analogs (eg, leuprolide acetate, 3.75 mg formulation).
- •c.Use of psychoactive medications (eg, selective serotonin reuptake inhibitors [SSRIs], serotonin norepinephrine reuptake inhibitors [SNRIs], tricyclic antidepressants), if used for chronic pain.
- •d.Use of selective estrogen receptor modulators (SERMs), including raloxifene, tamoxifen, and clomiphene.
- •- The use of the following drugs within 10 months before visit 1B (screening):
- •a.Injectable/implantable progestogens (eg, medroxyprogesterone acetate depot formulation).
- •b.Three (3)-month dose GnRH analogs (eg, leuprolide acetate, 11.25 mg formulation).
- •- Use of antiepileptic medications (eg, carbamazepine, gabapentin, lamotrigine).
- •- Transvaginal ultrasound (TVUS) findings requiring immediate surgical intervention, as determined by the investigator, and/or evidence of findings indicative of a secondary cause of pelvic pain other than endometriosis.
- •- A history of endometriosis-related symptoms that are completely relieved by mild analgesics.
- •- Abnormal cervical cytology smear (based on the Bethesda 2001 system). Subjects with reported atypical squamous cells of undetermined significance (ASCUS) may be considered if human papilloma virus (HPV) result is negative.
- •- Presence or history of the following:
- •a.Pelvic pain secondary to other disease processes (eg, pelvic masses other than endometriomas, genitourinary disease, fibromyalgia, pelvic inflammatory disease, gastrointestinal disease, irritable bowel syndrome).
- •b.Known history of or suspected endometrial hyperplasia or carcinoma.
- •c.Thrombophlebitis, thrombosis or thromboembolic disorders, deep vein thrombosis, pulmonary embolism, or known coagulopathy.
- •d.Ischemic heart disease, myocardial infarction, or unstable angina within 6 months before screening.
- •e.Cerebrovascular or cardiovascular disease.
- •f.Neuro-ocular disorders (eg, optic neuritis or retinal vein thrombosis).
- •g.Cholestasis or symptomatic gallstones (subjects who have had a cholecystectomy may be enrolled).
- •h.Valvular heart disease.
- •i.Breast cancer.
- •j.Estrogen-dependent neoplasia (eg, endometrial carcinoma, melanoma).
- •k.Liver tumors (benign or malignant).
- •l.Diabetes with vascular involvement, or uncontrolled diabetes.m.Undiagnosed abnormal genital bleeding within the past 6 months.
- •- Presence of the following:
- •a.Abnormality suggestive of malignancy noted on mammogram, breast examination, and/or ultrasound findings.
- •b.Malignancy, or treatment for malignancy, within the previous 10 years. History or active presence of basal cell or squamous cell carcinoma of the skin does not exclude the subject. History of no
研究者
相似试验
进行中（未招募）
1 期
This is a study to Evaluate the Safety and Efficacy of ABBV-154 in Subjects with Moderately to Severely Active Crohn's Disease (CD)Subjects with moderately to severely active Crohn's diseaseMedDRA version: 20.0Level: PTClassification code 10011401Term: Crohn's diseaseSystem Organ Class: 10017947 - Gastrointestinal disordersEUCTR2021-002869-18-BEAbbVie Deutschland GmbH & Co. KG265
进行中（未招募）
1 期
A study of safety and efficacy of NBI-74788 in Classic Congenital Adrenal HyperplasiaClassic Congenital Adrenal Hyperplasia (CAH)MedDRA version: 20.0Level: LLTClassification code 10010323Term: Congenital adrenal hyperplasiaSystem Organ Class: 100000004850EUCTR2019-004873-17-DEeurocrine Biosciences, Inc.165
进行中（未招募）
不适用
A study to evaluate the effect and safety of a 4 week treatment plan of Alirocumab in patients with high cholesterolPrimary HypercholesterolemiaMedDRA version: 17.0Level: LLTClassification code 10020604Term: HypercholesterolemiaSystem Organ Class: 100000004861EUCTR2013-002343-29-GBRegeneron Pharmaceuticals, Inc.803
进行中（未招募）
不适用
A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Tolerability of E5555, and its Effects on Markers of Intravascular Inflammation in Subjects with Coronary Artery Disease - E5555-G000-201Coronary Artery DiseaseMedDRA version: 8.1Level: PTClassification code 10011078EUCTR2005-006029-94-BEEisai Limited720
已完成
不适用
A Randomized, Double-Blind, Placebo-Controlled Study in Healthy Male Subjects to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single Ascending Oral Doses of JNJ-26070109abdominal pain and heartburn10017943NL-OMON30044Janssen-Cilag82